Mesalamine extended-release capsules recalled due to dissolution failure
Sun Pharmaceutical is recalling Mesalamine extended-release capsules due to failed dissolution specifications. The affected capsules may not dissolve and release medication properly.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall with no reported illnesses or injuries. The dissolution failure creates a risk of harm—medication ineffectiveness—but no adverse events have been reported. Therefore, the hazard is theoretical without reported injury, placing it at severity level 3 per the rubric.
Plain-English summary
Sun Pharmaceutical Industries Inc. is recalling Mesalamine extended-release capsules, USP 500mg, due to failed dissolution specifications. Approximately 54,960 bottles were distributed nationwide in the United States.
In pharmaceuticals, dissolution refers to how a medication dissolves and releases in the body. The recalled capsules failed to meet the specified dissolution requirements.
The affected product can be identified by NDC number 63304-089-13. Specific lot numbers with expiration dates ranging from April 2024 to September 2024 are included in this recall. The manufacturer has provided detailed lot number information to pharmacies and healthcare providers.
Patients using the recalled product should contact their healthcare provider or pharmacist. Do not stop medication without speaking to your healthcare professional. Return the recalled product to your pharmacy for a replacement.
The recalled product
- Product
- MESALAMINE (MESALAMINE)
- Brand
- MESALAMINE
- Manufacturer
- SUN PHARMACEUTICAL INDUSTRIES INC
- Category
- Drug — Gastrointestinal
- Hazard
- Affected units
- 54,960
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot #s: MHD0606A
- MHD0612A
- Exp. 04/30/2024
- MHD0613A
- MHD0652A
- MHD0657A
- MHD0672A
- MHD0673A
- Exp. 05/31/2024
- MHD0767A
- MHD0768A
- MHD0769A
- MHD0785A
- MHD0799A
- MHD0800A
- MHD0801A
- Exp. 06/30/2024
- MHD0827A
- MHD0828A
- MHD0875A
UPCs (1)
- 0363304089134
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · MESALAMINE
- ModerateMesalamine Tablets Recalled for Manufacturing Equipment Microbial Contamination
FDA (Drugs) · 2024-01-31
- ModerateTeva Recalls Mesalamine Tablets Due to Failed Dissolution Testing
FDA (Drugs) · 2020-11-18
- ModerateTeva Recalls Mesalamine Tablets Due to Dissolution Test Failures
FDA (Drugs) · 2020-03-11
Same manufacturer · SUN PHARMACEUTICAL INDUSTRIES INC
See all →- HighSun Pharmaceutical Recalls Carbamazepine Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2026-08-26
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08
- HighPerampanel Prescription Tablets Recalled for Labeling Mix-up
FDA (Drugs) · 2026-07-01
- HighBudesonide inhalation ampules contain black and brown specks and particles
FDA (Drugs) · 2026-06-17
- SevereDoxorubicin liposome injection vials contain glass particulate matter
FDA (Drugs) · 2026-06-17
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- ModerateChlorthalidone 25mg tablets failed dissolution specifications in two batches
FDA (Drugs) · 2026-06-24
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- ModerateMinocycline extended-release tablets failed dissolution testing during stability analysis
FDA (Drugs) · 2026-06-17